High valuations on pharma stocks and high drug prices not justified

By Kevin Wilson

Wall Street has long had a love affair with biotechnology and pharma stocks, and their prices have soared in recent years. Profit growth has been tremendous in some cases, but not always because of good returns on R&D investments; rather, merger activity and inflated drug prices appear to be a major part of the mix.”…

[Click HERE to read the full article]